INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.02
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.31

24 Mar
2025

-0.050

OPEN

$2.30

-2.12%

HIGH

$2.34

703,039

LOW

$2.30

TARGET
$3.123 35.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 26.0 8.5 xxx
DPS (cps) xxx 5.8 6.2 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 3.3% 6.0% xxx
PE Ratio xxx N/A 27.3 xxx
Dividend Yield xxx N/A 2.7% xxx
Div Pay Ratio(%) xxx N/A 72.6% xxx

Dividend yield today if purchased 3 years ago: 1.52%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.46

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-26.0
DPS All xxxxxxxxxxxxxxx5.8
Sales/Revenue xxxxxxxxxxxxxxx469.7 M
Book Value Per Share xxxxxxxxxxxxxxx129.0
Net Operating Cash Flow xxxxxxxxxxxxxxx66.2 M
Net Profit Margin xxxxxxxxxxxxxxx-12.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-17.99 %
Return on Invested Capital xxxxxxxxxxxxxxx-8.89 %
Return on Assets xxxxxxxxxxxxxxx-7.67 %
Return on Equity xxxxxxxxxxxxxxx-17.99 %
Return on Total Capital xxxxxxxxxxxxxxx6.00 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx28.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx16 M
Long Term Debt xxxxxxxxxxxxxxx342 M
Total Debt xxxxxxxxxxxxxxx358 M
Goodwill - Gross xxxxxxxxxxxxxxx373 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx42 M
Price To Book Value xxxxxxxxxxxxxxx2.07

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx23.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.08 %
Cost of Goods Sold xxxxxxxxxxxxxxx366 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx62 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

27/02/2025

1

Buy

$3.59

55.41%

Integral Diagnostics’ 1H earnings (EBITDA) of $64m were in line with Bell Potter's expectation, but softer volume growth and higher costs weighed on margins. 

The pro-forma earnings margin was circa 19.6% compared to the analysts' 21% forecast.

Revenue of $232m increased 8% year-on-year, with MRI and PET services outperforming other diagnostic segments, highlight the analysts.

Management reaffirmed the FY25 outlook, expecting 2H cost pressures to stabilise and operational efficiencies to improve.

Bell Potter lowers the target price to $3.59 from $3.87 and retains a Buy rating. The broker believes the negative share market reaction to the interim result creates a buying opportunity for investors.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 5.20 cents and EPS of 7.40 cents.
Bell Potter forecasts a full year FY26 dividend of 8.00 cents and EPS of 11.40 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

05/03/2025

1

Upgrade to Buy from Hold

$2.90

25.54%

In its first results since acquiring Capitol Health, Integral Diagnostics posted an operating EBITDA margin that missed estimates.

Canaccord Genuity believes the resulting sell-off was unwarranted, particularly as there is a path to margin improvement on the acquisition.

There is also the prospect of -$10m in synergies most of which will be recognised in the first year, with the potential for longer term synergies not taken into account.

The broker raises its target to $2.90 from $2.50 and upgrades to Buy from Hold.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 5.90 cents and EPS of 8.40 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 9.40 cents and EPS of 13.50 cents.

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
Rudi’s View: Best Buys In Copper, Small Caps, Tech, Healthcare, And More

Mar 20 2025 - Rudi's View
2
ESG Focus: Fund Flows, Tariffs, Defence & AI

Mar 20 2025 - ESG Focus
3
February Result Season 2025: The Wrap

Mar 14 2025 - Feature Stories
4
Next Week At A Glance – 17-21 Mar 2025

Mar 14 2025 - Weekly Reports
5
Rudi’s View: Post February Conviction Calls

Mar 13 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps